Pudu Robotics Unveils PUDU D5 Series: Industry-Grade Autonomous Quadruped Robots Designed for Complex, Real-World Operations
SHENZHEN, China, Dec. 2, 2025 /PRNewswire/ — Pudu Robotics, a global leader in service robotics, today announced the launch of the PUDU D5 Series, a new generation of Industry-grade Autonomous Quadruped Robots engineered for complex, unstructured, and large-scale outdoor environments.…
Former Commander of U.S. Central Command General Michael “Erik” Kurilla Joins Operation Healing Forces Board of Directors
TAMPA, Fla., Dec. 2, 2025 /PRNewswire/ — Operation Healing Forces (OHF) proudly announces the appointment of retired U.S. Army General Michael “Erik” Kurilla, former Commander of United States Central Command (CENTCOM), to its Board of Directors. His leadership and deep…
Trump calls for Dulles rebuild as new concourse rises
Even as a major expansion project is already under construction, President Donald Trump wants to rebuild Washington Dulles International Airport.
ATYR Deadline: ATYR Investors with Losses Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit
NEW YORK, Dec. 2, 2025 /PRNewswire/ —
Edwards & Ragatz, P.A. Ranked Among Top 100 Wrongful Death Verdicts in the United States
JACKSONVILLE, Fla., Dec. 2, 2025 /PRNewswire/ — Edwards & Ragatz, P.A. has been recognized by Top Verdict™ for securing one of the Top 100 Wrongful Death Verdicts in the United States for 2024. The firm’s $4.5 million medical malpractice verdict…
Hyundai Motor Group Unveils Production-Ready Autonomous Mobility Robot Platform 'MobED' at iREX 2025
MobED, Hyundai Motor Group Robotics LAB’s first mass-produced mobility robot platform, is designed for diverse industrial and everyday applicationsMobED debuts an innovative approach to robotics functionality, defined by Adaptive Mobility (H/W), Intuitive Autonomy (S/W) and Infinite Journey (applications)MobED features AI-based…
Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®
FDA approval of OMLYCLO® (omalizumab-igec) 300 mg/2 mL solution in a single-dose prefilled syringe for subcutaneous injection expands dosing flexibility and supports tailored treatment for individual patients with certain allergic diseasesOMLYCLO® (omalizumab-igec) is the first and only biosimilar designated as…
Avianca Reports Third Quarter 2025 Financial Results:
Delivered $411 Million in EBITDAR – a 15% Year-over-Year Increase – and Achieved Credit Rating Upgrades on the back of Solid Performance
CNOOC Limited Brings On-stream Weizhou 11-4 Oilfield Adjustment and Satellite Fields Development Project
HONG KONG, Dec. 2, 2025 /PRNewswire/ — CNOOC Limited (the “Company”, SEHK: 00883 (HKD Counter) and 80883 (RMB Counter), SSE: 600938) today announces that Weizhou 11-4 Oilfield Adjustment and Satellite Fields Development Project has commenced production.